Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR1 D647N |
| Therapy | Erdafitinib |
| Indication/Tumor Type | breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 D647N | breast cancer | sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) treatment resulted in decreased Fgfr1 phosphorylation in a cell line expressing FGFR1 D647N and reduced migration in breast cancer cells expressing FGFR1 D647N in culture (PMID: 37778450). | 37778450 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37778450) | The D647N mutation of FGFR1 induces ligand-independent receptor activation. | Full reference... |